Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 288

1.

Strategies to increase the donor pool and access to kidney transplantation: an international perspective.

Maggiore U, Oberbauer R, Pascual J, Viklicky O, Dudley C, Budde K, Sorensen SS, Hazzan M, Klinger M, Abramowicz D; for the ERA-EDTA-DESCARTES Working Group.

Nephrol Dial Transplant. 2014 Jun 6. pii: gfu212. [Epub ahead of print] Review.

PMID:
24907023
[PubMed - as supplied by publisher]
Free Article
2.

The severity of acute cellular rejection defined by banff classification is associated with kidney allograft outcomes.

Wu K, Budde K, Lu H, Schmidt D, Liefeldt L, Glander P, Neumayer HH, Rudolph B.

Transplantation. 2014 Jun 15;97(11):1146-54. doi: 10.1097/01.TP.0000441094.32217.05.

PMID:
24892962
[PubMed - in process]
3.

Anemia control in kidney transplant recipients using once-monthly continuous erythropoietin receptor activator: a prospective, observational study.

Budde K, Rath T, Kliem V.

J Transplant. 2014;2014:179705. doi: 10.1155/2014/179705. Epub 2014 May 4.

PMID:
24883202
[PubMed]
Free PMC Article
4.

Review of Bortezomib Treatment of Antibody-Mediated Rejection in Renal Transplantation.

Ejaz NS, Alloway RR, Halleck F, Dürr M, Budde K, Woodle ES.

Antioxid Redox Signal. 2014 Apr 28. [Epub ahead of print]

PMID:
24635140
[PubMed - as supplied by publisher]
5.

Acute cellular rejection with isolated v-lesions is not associated with more favorable outcomes than vascular rejection with more tubulointerstitial inflammations.

Wu KY, Budde K, Schmidt D, Neumayer HH, Rudolph B.

Clin Transplant. 2014 Apr;28(4):410-8. doi: 10.1111/ctr.12333. Epub 2014 Mar 11.

PMID:
24617534
[PubMed - in process]
6.

Genetic polymorphisms in IL-2, IL-10, TGF-β1, and IL-2RB and acute rejection in renal transplant patients.

Chen Z, Bouamar R, Van Schaik RH, De Fijter JW, Hartmann A, Zeier M, Budde K, Kuypers DR, Weimar W, Hesselink DA, Van Gelder T.

Clin Transplant. 2014 Jun;28(6):649-55. doi: 10.1111/ctr.12346. Epub 2014 Jun 3.

PMID:
24579958
[PubMed - in process]
7.

Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms.

Duran I, Goebell PJ, Papazisis K, Ravaud A, Weichhart T, Rodriguez-Portal JA, Budde K.

Expert Opin Drug Saf. 2014 Mar;13(3):361-72. doi: 10.1517/14740338.2014.888056. Epub 2014 Feb 11.

PMID:
24517115
[PubMed - in process]
8.

Complement-binding anti-HLA antibodies and kidney transplantation.

Baid-Agrawal S, Lachmann N, Budde K.

N Engl J Med. 2014 Jan 2;370(1):84. doi: 10.1056/NEJMc1313506#SA2. No abstract available.

PMID:
24382077
[PubMed - indexed for MEDLINE]
9.

Proteinuria and sirolimus after renal transplantation: a retrospective analysis from a large German multicenter database.

Naik MG, Heller KM, Arns W, Budde K, Diekmann F, Eitner F, Fischereder M, Goßmann J, Heyne N, Morath C, Riester U, Gwinner W, Jürgensen JS; German Sirolimus Study Group.

Clin Transplant. 2014 Jan;28(1):67-79. doi: 10.1111/ctr.12280. Epub 2013 Dec 26.

PMID:
24372584
[PubMed - in process]
10.

The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open-label comparative study.

Mühlbacher F, Neumayer HH, del Castillo D, Stefoni S, Zygmunt AJ, Budde K; European Rapamune Cyclosporine Minimization Study Group.

Transpl Int. 2014 Feb;27(2):176-86. doi: 10.1111/tri.12228. Epub 2013 Nov 25.

PMID:
24266855
[PubMed - in process]
11.

Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study.

Stoelben S, Arns W, Renders L, Hummel J, Mühlfeld A, Stangl M, Fischereder M, Gwinner W, Suwelack B, Witzke O, Dürr M, Beelen DW, Michel D, Lischka P, Zimmermann H, Rübsamen-Schaeff H, Budde K.

Transpl Int. 2014 Jan;27(1):77-86. doi: 10.1111/tri.12225. Erratum in: Transpl Int. 2014 Apr;27(4):416.

PMID:
24164420
[PubMed - in process]
12.

Volume matters: CT-based renal cortex volume measurement in the evaluation of living kidney donors.

Halleck F, Diederichs G, Koehlitz T, Slowinski T, Engelken F, Liefeldt L, Friedersdorff F, Fuller TF, Magheli A, Neumayer HH, Budde K, Waiser J.

Transpl Int. 2013 Dec;26(12):1208-16. doi: 10.1111/tri.12195. Epub 2013 Oct 19.

PMID:
24118327
[PubMed - in process]
13.

Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients.

Elens L, Hesselink DA, Bouamar R, Budde K, de Fijter JW, De Meyer M, Mourad M, Kuypers DR, Haufroid V, van Gelder T, van Schaik RH.

Ther Drug Monit. 2014 Feb;36(1):71-9. doi: 10.1097/FTD.0b013e31829da6dd.

PMID:
24061445
[PubMed - in process]
14.

In situ genetic association for serotiny, a fire-related trait, in Mediterranean maritime pine (Pinus pinaster).

Budde KB, Heuertz M, Hernández-Serrano A, Pausas JG, Vendramin GG, Verdú M, González-Martínez SC.

New Phytol. 2014 Jan;201(1):230-41. doi: 10.1111/nph.12483. Epub 2013 Sep 10.

PMID:
24015853
[PubMed - indexed for MEDLINE]
15.

Frequency and long-term outcomes of post-transplant hypophosphatemia after kidney transplantation.

Huber L, Naik M, Budde K.

Transpl Int. 2013 Oct;26(10):e94-6. doi: 10.1111/tri.12145. Epub 2013 Aug 12. No abstract available.

PMID:
23937423
[PubMed - indexed for MEDLINE]
16.

Treatment with sirolimus is associated with less weight gain after kidney transplantation.

Diekmann F, Campistol JM, Rovira J, Budde K, Neumayer HH, Oppenheimer F, Flechner SM.

Transplantation. 2013 Sep 15;96(5):480-6. doi: 10.1097/TP.0b013e31829a9231.

PMID:
23912169
[PubMed - indexed for MEDLINE]
17.

Efficacy of sotrastaurin plus tacrolimus after de novo kidney transplantation: randomized, phase II trial results.

Russ GR, Tedesco-Silva H, Kuypers DR, Cohney S, Langer RM, Witzke O, Eris J, Sommerer C, von Zur-Mühlen B, Woodle ES, Gill J, Ng J, Klupp J, Chodoff L, Budde K.

Am J Transplant. 2013 Jul;13(7):1746-56. doi: 10.1111/ajt.12251. Epub 2013 May 13.

PMID:
23668931
[PubMed - indexed for MEDLINE]
Free Article
18.

Sotrastaurin in calcineurin inhibitor-free regimen using everolimus in de novo kidney transplant recipients.

Tedesco-Silva H, Kho MM, Hartmann A, Vitko S, Russ G, Rostaing L, Budde K, Campistol JM, Eris J, Krishnan I, Gopalakrishnan U, Klupp J.

Am J Transplant. 2013 Jul;13(7):1757-68. doi: 10.1111/ajt.12255. Epub 2013 May 9.

PMID:
23659755
[PubMed - indexed for MEDLINE]
Free Article
19.

New perspectives of immunosuppression.

Halleck F, Friedersdorff F, Fuller TF, Matz M, Huber L, Dürr M, Schütz M, Budde K.

Transplant Proc. 2013 Apr;45(3):1224-31. doi: 10.1016/j.transproceed.2013.02.033. Review.

PMID:
23622665
[PubMed - indexed for MEDLINE]
20.

A randomized trial of intensified vs. standard dosing for enteric-coated mycophenolate sodium in de novo kidney transplant recipients: results at 1 year.

Arns W, Sommerer C, Glander P, Ariatabar T, Porstner M, May C, Paulus EM, Shipkova M, Fischer W, Liefeldt L, Hackenberg R, Schemmer P, Domhan S, Zeier M, Budde K.

Clin Nephrol. 2013 Jun;79(6):421-31. doi: 10.5414/CN107908.

PMID:
23611518
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk